Mildronate, an inhibitor of carnitine biosynthesis, induces an increase in gamma-butyrobetaine contents and cardioprotection in isolated rat heart infarction

Simple item page
dc.contributor.authorLiepinsh, Edgars
dc.contributor.authorVilskersts, Reinis
dc.contributor.authorLoca, Dagnija
dc.contributor.authorKirjanova, Olga
dc.contributor.authorPugovichs, Osvalds
dc.contributor.authorKalvinsh, Ivars
dc.contributor.authorDambrova, Maija
dc.date.accessioned2021-06-30T13:00:01Z
dc.date.available2021-06-30T13:00:01Z
dc.date.issued2006-12
dc.description.abstractThe inhibition of gamma-butyrobetaine (GBB) hydroxylase, a key enzyme in the biosynthesis of carnitine, contributes to lay ground for the cardioprotective mechanism of action of mildronate. By inhibiting the biosynthesis of carnitine, mildronate is supposed to induce the accumulation of GBB, a substrate of GBB hydroxylase. This study describes the changes in content of carnitine and GBB in rat plasma and heart tissues during long-term (28 days) treatment of mildronate [i.p. (intraperitoneal) 100 mg/kg/daily]. Obtained data show that in concert with a decrease in carnitine concentration, the administration of mildronate caused a significant increase in GBB concentration. We detected about a 5-fold increase in GBB contents in the plasma and brain and a 7-fold increase in the heart. In addition, we tested the cardioprotective effect of mildronate in isolated rat heart infarction model after 3, 7, and 14 days of administration. We found a statistically significant decrease in necrotic area of infarcted rat hearts after 14 days of treatment with mildronate. The cardioprotective effect of mildronate correlated with an increase in GBB contents. In conclusion, our study, for the first time, provides experimental evidence that the long-term administration of mildronate not only decreases free carnitine concentration, but also causes a significant increase in GBB concentration, which correlates with the cardioprotection of mildronate.en
dc.description.statusPeer reviewed
dc.format.extent6
dc.format.extent156748
dc.identifier.citationLiepinsh, E, Vilskersts, R, Loca, D, Kirjanova, O, Pugovichs, O, Kalvinsh, I & Dambrova, M 2006, 'Mildronate, an inhibitor of carnitine biosynthesis, induces an increase in gamma-butyrobetaine contents and cardioprotection in isolated rat heart infarction', Journal of Cardiovascular Pharmacology, vol. 48, no. 6, pp. 314-319. https://doi.org/10.1097/01.fjc.0000250077.07702.23
dc.identifier.doi10.1097/01.fjc.0000250077.07702.23
dc.identifier.issn0160-2446
dc.identifier.urihttps://dspace.rsu.lv/jspui/handle/123456789/5751
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=33846117009&partnerID=8YFLogxK
dc.language.isoeng
dc.relation.ispartofJournal of Cardiovascular Pharmacology
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subject3.1 Basic medicine
dc.subject1.1. Scientific article indexed in Web of Science and/or Scopus database
dc.subjectPharmacology
dc.subjectCardiology and Cardiovascular Medicine
dc.titleMildronate, an inhibitor of carnitine biosynthesis, induces an increase in gamma-butyrobetaine contents and cardioprotection in isolated rat heart infarctionen
dc.type/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Mildronate_an_Inhibitor_of_Carnitine_Biosynthesis.pdf
Size:
153.07 KB
Format:
Adobe Portable Document Format
Download

Collections

Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure